Quotes

1. While we have been actively advancing our lesion assessment technology for the last two years, we are very pleased to see that the significant Series B investment will give MedLumics the means to complete our best-in-class product, conduct a series of international clinical trials to prove its safety and efficacy, and market it to specialist centers. As the company advances and grows into new areas, we will now expand and develop the team internationally.

   In MedLumics Secures 34.4 Million Euros in Series B Funding for OCT Guided Treatment of Atrial Fibrillation

2. These promising results show the potential of optical imaging to guide minimally invasive therapeutic procedures and improve accuracy and patient safety...“Thanks to the years of development built into our technology, we are in a position to introduce this innovation into a practical RF ablation product.

   In MedLumics Technology Validated for Real-time Assessment of Catheter Ablation Treatment of Atrial Fibrillation in Pre-clinical Feasibility Study

3. NITID is the result of a decade of research in optical miniaturization technology, and we are thrilled to introduce it at EADV...NITID integrates three imaging modalities in one easy-to-use probe, thereby enabling physicians to produce high-quality images of a patient’s skin and determine whether skin cancer is present without an invasive biopsy. We believe NITID is a gateway into the future of personalized dermatology, supporting the introduction of new non-surgical treatments, and could not be more pleased with the positive reception and validation it received at EADV.

   In MedLumics Introduces NITID Skin Imaging System at EADV

4. This unique collaboration of leading European technology and clinical centers will allow us to significantly extend the technical possibilities and clinical indications of our micro-chip based OCT system

   In MedLumics Announces “BiopsyPen Project” with €3.6M EU in Funding; Initiative Aimed at New Clinical Applications for Optical Coherence Tomography

5. We believe our proprietary platform technology has the potential to transform the field of diagnostics and therapy guidance across a number of clinical segments, including dermatology, where we will initially focus...Our first product offering combines a tested, real-world technology that provides basic surface information with an advanced sectional imaging modality that was up to now only available in research-oriented systems. This results in a compact, easy-to-use system that gives physicians the ability to perform rapid and advanced diagnostics at the point of care and, as a result, to provide better therapies to their patients.

   In MedLumics Expands Management Team in Preparation for 2014 Launch of First Generation Diagnostic Imaging System for Dermatology

6. "The Series A financing is a major achievement for MedLumics that aligns us with top-tier life science investment partners who believe in the tremendous potential of our microchip-based OCT technology...We believe this investment speaks to the exceptional clinical value it will ultimately bring to physicians and patients.

   In MedLumics Announces 3.5 Million Euro/4.7 Million USD Series A Financing, Led by Ysios Capital Partners and “la Caixa”